Results 101 to 110 of about 13,799 (205)

Cancer therapy-induced ototoxicity: Current challenges and emerging management strategies. [PDF]

Animal Model Exp Med
Huang Y, Xu B, Chen X, Chen Y, Yu D.
europepmc   +1 more source

Pharmacogenetic strategies to mitigate cisplatin-induced ototoxicity in head and neck cancer: A cost-minimization analysis with the use of GSTP1 c.313A>G genotyping. [PDF]

PLoS One
Macedo LT, Ferrari VE, Dias Costa EF, Lourenço GJ, Calonga L, Castilho AM, Chone CT, Passos Lima CS.   +7 more
europepmc   +1 more source

Progressive Sensorineural Hearing Loss Following Cisplatin Chemotherapy: Mechanisms Underlying Cochlear Retention and Long-Term Ototoxicity. [PDF]

Pharmaceuticals (Basel)
Ruggiero A, Picciotti PM, Mastrangelo S, Romano A, Talloa D, Galli J, Attinà G.   +6 more
europepmc   +1 more source

An integration of physiological, morphological and biochemical assessments in studying guinea pig models of ototoxicity and otoprotection-a systematic review. [PDF]

Curr Res Toxicol
Young YH, Wu PH, Liu SH.
europepmc   +1 more source

Exploring and Overcoming Challenges for Efficient Audiological Testing in Children Under 5 Years of Age-Screening with Otoacoustic Emissions. [PDF]

Audiol Res
Streefkerk N, Diepstraten FA, Veld EAHI', Am Zehnhoff-Dinnesen A, Grotel MV, Neumann K, Meijer AJM, Amant F, Parfitt R, Verešpejová L, Brock PR, Hunter LL, Helleman HW, Brooks B, Rajput KM, Knight K, van den Heuvel-Eibrink MM, Hoetink AE.   +17 more
europepmc   +1 more source

Impact of cisplatin dose, renal function, and other factors on audiometrically-assessed ototoxicity in more than 1400 adult-onset cancer survivors from The Platinum Study: a multicentre cohort study. [PDF]

EClinicalMedicine
Sanchez VA, Dinh PC, Monahan PO, Fung C, Althouse S, Stump T, Rooker J, Dolan ME, Feldman DR, Hamilton RJ, Pierorazio PM, Martin NE, Huddart R, Kollmannsberger C, Root J, Sesso HD, Weinzierl M, Einhorn LH, Frisina RD, Travis LB.   +19 more
europepmc   +1 more source

Activating GPR55 protects cochlear hair cells against cisplatin-induced ototoxicity via inhibiting MAPK pathway. [PDF]

Sci Rep
Guo L, Wang R, Wang Y, Ruan H, Zhang Y, Wei Y, Du J, Fang Q, Yang J, Cao W.   +9 more
europepmc   +1 more source

Early Detection of Ototoxicity Using Serial Mobile Audiometry, Otoacoustic Emissions Testing, and Inner Ear Biomarker Measurement in Patients Receiving Platinum-Based Chemotherapy Treatment: It is Feasible to Implement in a National Health Service (NHS) Cancer Ambulatory Care Setting. [PDF]

Otol Neurotol
Mehta N, Awad A, Forbes M, Iliadou E, Katiri R, Ferdous T, Lowe H, Ensell L, Alifrangis C, Schilder AGM, Windsor R.   +10 more
europepmc   +1 more source

Correction: Histone deacetylase inhibitors are protective in acute but not in chronic models of ototoxicity. [PDF]

Front Cell Neurosci
Yang CH, Liu Z, Dong D, Schacht J, Arya D, Sha SH.   +5 more
europepmc   +1 more source

Identifying Gaps and Opportunities to Improve Ototoxicity Management in Veterans With Cancer: Evidence From a Retrospective Cohort and Oncology Provider Survey. [PDF]

Cancer Med
Lacey C, Clark K, Debacker JR, Stuehm H, Hungerford M, Milnes T, Johansson K, Mannino R, Graff JN, Konrad-Martin D.   +9 more
europepmc   +1 more source